LEON HELLMAN, M.D., F.A.C.P.; BARNETT ZUMOFF, M.D.; GERALD KESSLER, PH.D.; ELMER KARA, M.D.; IRA L. RUBIN, M.D., F.A.C.P.; ROBERT S. ROSENFELD, PH.D.
Thorp and Waring (1) studied a series of aryloxyisobutyric acids in rats for their ability to lower the level of cholesterol and lipids in serum and liver and found the compounds with maximum activity and minimum toxicity to be p-chlorophenoxyisobutyric acid (CPIB) or its ethyl ester, clofibrate (ethyl p-chlorophenoxyisobutyric acid) (CPIB ester). Because the cholesterol-lowering activity of CPIB ester (Figure 1) in treated rats appeared to coincide in time with spontaneous reductions in the serum cholesterol of control rats, the hypothesis was developed that CPIB ester augmented a rhythmic endogenous hypocholesteremic mechanism. Evidence was adduced that increases in adrenal cortical
HELLMAN L, ZUMOFF B, KESSLER G, KARA E, RUBIN IL, ROSENFELD RS. Reduction of Cholesterol and Lipids in Man by Ethyl p-Chlorophenoxyisobutyrate. Ann Intern Med. ;59:477–494. doi: 10.7326/0003-4819-59-4-477
Download citation file:
Published: Ann Intern Med. 1963;59(4):477-494.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use